Gene: VEGFD
Official Full Name: vascular endothelial growth factor Dprovided by HGNC
Gene Summary: The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor C. Read-through transcription has been observed between this locus and the upstream PIR (GeneID 8544) locus. [provided by RefSeq, Feb 2011]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO10441 | VEGFD Knockout cell line (A549) | Human | VEGFD | 1:3~1:4 | Negative | Online Inquiry |
VEGFD Gene Knockout Cell Lines are innovative biological tools specifically engineered to facilitate the study of vascular endothelial growth factor-D (VEGFD) within various cellular contexts. These cell lines are pivotal in examining the role of VEGFD in pathological processes, particularly in oncogenesis, lymphangiogenesis, and tissue repair. By systematically disrupting the VEGFD gene using CRISPR/Cas9 technology, researchers can create a controlled environment to analyze the downstream effects of VEGFD signaling pathways and their impact on cellular behaviors such as proliferation, migration, and apoptosis.
The primary mechanism of action lies in the knockout of the VEGFD gene, effectively eliminating its expression. This allows researchers to observe changes in cellular functions without the influence of VEGFD. These changes can reveal critical insights into the angiogenic processes underlying numerous diseases, including cancer and chronic inflammation. Additionally, the knockout cell lines serve as a valuable resource for drug discovery and validation, allowing scientists to assess the therapeutic potential of novel compounds targeting the VEGFD pathway.
The scientific importance of VEGFD Gene Knockout Cell Lines extends beyond basic research; they are instrumental in preclinical studies aimed at developing anti-cancer therapies or treatments for lymphatic disorders. Moreover, unlike traditional methods that may rely on non-specific inhibitors or siRNA, these knockout cell lines provide a permanent and precise approach to gene disruption, thus ensuring reproducibility and accuracy in experimental outcomes.
The unique selling points of these cell lines lie in their robustness, ease of integration into existing research frameworks, and compatibility with high-throughput screening techniques. They offer unparalleled reliability when evaluating the functional consequences of VEGFD absence, making them indispensable tools for clinicians and researchers probing angiogenesis-related conditions.
Ultimately, VEGFD Gene Knockout Cell Lines represent an essential addition to the researcher’s toolkit, enhancing their ability to make significant strides in understanding vascular biology. Our company specializes in delivering high-quality biological products tailored to the needs of the scientific community, ensuring that our offerings remain at the forefront of innovation and reliability. With our expertise, we empower researchers to push the boundaries of scientific discovery.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.